Telix and SHINE partner for Lutetium-177 Supply
10. Februar 2022 16:09 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with...
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
08. Februar 2022 17:27 ET
|
Telix Pharmaceuticals Limited
MELBOURNE and LIEGE, Belgium, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a global clinical supply agreement with Berlin-based...
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
26. Januar 2022 16:51 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s...
Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
18. August 2021 18:47 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today releases details of two ancillary studies under the ProstACT program...
Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
09. Mai 2021 19:13 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC)...
Prostate Cancer Pipeline Insights: Comprehensive Analysis of Key Emerging Therapies and Pharmaceutical Companies
22. März 2021 21:40 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, March 22, 2021 (GLOBE NEWSWIRE) -- Prostate Cancer Pipeline Insights: Comprehensive Analysis of Key Emerging Therapies and Pharmaceutical Companies With over 900 key...